Teicoplanin Injectable (Iv/Im) Suppliers & Bulk Manufacturers

Available Forms: Injectable (IV/IM)

Available Strengths: 200 mg/100 mL, 400 mg/200 mL, 400 mg/100 mL

Reference Brands: Targocid, Tolocin(US & EU)

Category: Antibiotics

Teicoplanin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, causing bacterial lysis. It is effective against gram-positive bacteria, including MRSA. Benefits include long half-life allowing once-daily dosing, rapid bacterial eradication, and safety for severe infections like endocarditis and osteomyelitis, when used properly under supervision.

Product Description:

Teicoplanin injectable is approved in the EU and US for severe gram-positive bacterial infections, including MRSA. In the EU, brands like Targocid are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, approval is limited, with extraregional use mainly in Europe and Asia. Both regions require detailed dossiers, including clinical trial data, manufacturing practices, and pharmacovigilance plans for approval and ongoing safety. For expert support on regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for teicoplanin IV formulations, ensuring adherence to European and US standards for safe, effective antimicrobial therapy.